Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for FT218 in Adults with Narcolepsy for the Treatment of Excessive Daytime Sleepiness and Cataplexy
Avadel Pharmaceuticals announced this week that the U.S. Food and Drug Administration (FDA) has accepted...